[go: up one dir, main page]

DK1151102T3 - Glycosylerede leptinpræparater og relaterede fremgangsmåder - Google Patents

Glycosylerede leptinpræparater og relaterede fremgangsmåder

Info

Publication number
DK1151102T3
DK1151102T3 DK00911784T DK00911784T DK1151102T3 DK 1151102 T3 DK1151102 T3 DK 1151102T3 DK 00911784 T DK00911784 T DK 00911784T DK 00911784 T DK00911784 T DK 00911784T DK 1151102 T3 DK1151102 T3 DK 1151102T3
Authority
DK
Denmark
Prior art keywords
proteins
glycosylated
glycosylated leptin
leptin
methods
Prior art date
Application number
DK00911784T
Other languages
English (en)
Inventor
Steven G Elliott
Frances H Martin
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Application granted granted Critical
Publication of DK1151102T3 publication Critical patent/DK1151102T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/5759—Products of obesity genes, e.g. leptin, obese (OB), tub, fat
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Emergency Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
DK00911784T 1999-02-12 2000-02-11 Glycosylerede leptinpræparater og relaterede fremgangsmåder DK1151102T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US24967599A 1999-02-12 1999-02-12

Publications (1)

Publication Number Publication Date
DK1151102T3 true DK1151102T3 (da) 2006-05-29

Family

ID=22944511

Family Applications (1)

Application Number Title Priority Date Filing Date
DK00911784T DK1151102T3 (da) 1999-02-12 2000-02-11 Glycosylerede leptinpræparater og relaterede fremgangsmåder

Country Status (11)

Country Link
EP (1) EP1151102B1 (da)
JP (1) JP4841037B2 (da)
AT (1) ATE323766T1 (da)
AU (1) AU781460B2 (da)
CA (1) CA2359840C (da)
CY (1) CY1107470T1 (da)
DE (1) DE60027409T2 (da)
DK (1) DK1151102T3 (da)
ES (1) ES2257287T3 (da)
PT (1) PT1151102E (da)
WO (1) WO2000047741A1 (da)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002079415A2 (en) * 2001-03-30 2002-10-10 Lexigen Pharmaceuticals Corp. Reducing the immunogenicity of fusion proteins
CA2459015A1 (en) * 2001-08-29 2003-03-13 The University Of Buckingham Use of leptin for infant with low birth weight for prevention of obesity
SI2219031T1 (sl) * 2001-10-22 2013-11-29 Amgen, Inc. Uporaba leptina za zdravljenje lipoatrofije pri ljudeh in metoda za ugotavljanje dovzetnosti za navedeno zdravljenje
US7094579B2 (en) * 2002-02-13 2006-08-22 Xoma Technology Ltd. Eukaryotic signal sequences for prokaryotic expression
EP1587923B1 (en) 2003-01-22 2011-08-24 Duke University Improved constructs for expressing lysosomal polypeptides
US20070141666A1 (en) 2003-09-26 2007-06-21 Applied Research Systems Ars Holding N.V. Leader sequences for use in production of proteins
ES2566670T3 (es) 2004-10-29 2016-04-14 Ratiopharm Gmbh Remodelación y glucopegilación del factor de crecimiento de fibroblastos (FGF)
WO2008067599A1 (en) * 2006-12-04 2008-06-12 Apollo Life Sciences Limited Isolated leptin and adiponectin molecules and chimeric molecules thereof
EP2170919B8 (en) 2007-06-12 2016-01-20 ratiopharm GmbH Improved process for the production of nucleotide sugars
JP2009126856A (ja) * 2007-11-28 2009-06-11 Fancl Corp 血中中性脂肪上昇抑制剤
AU2009248914A1 (en) 2008-05-21 2009-11-26 Neurotez, Inc. Methods for Treating Neurodegenerative Disorders Related to Neurofibrillary Tangles
WO2009149379A2 (en) 2008-06-05 2009-12-10 Regents Of The University Of Michigan Use of leptin for the treatment of fatty liver diseases and conditions
AU2009313562B2 (en) 2008-11-04 2012-11-15 Neurotez, Inc. Leptin compositions and methods for treating progressive cognitive function disorders resulting from accumulation of neurofibrillary tangles and amlyoid beta
JP6174489B2 (ja) 2010-09-28 2017-08-02 アエゲリオン ファーマシューティカルズ，インコーポレイテッド 高可溶性レプチン
CN108524919A (zh) 2012-05-17 2018-09-14 延伸生物科学股份有限公司 用于改进的药物递送的载体
HUE040496T2 (hu) 2012-09-27 2019-03-28 Childrens Medical Ct Corp Vegyületek elhízás kezelésére és alkalmazási eljárásaik
JP6672157B2 (ja) 2013-11-26 2020-03-25 ザ チルドレンズ メディカル センター コーポレーション 肥満を処置するための化合物およびその使用方法
WO2015153933A1 (en) 2014-04-03 2015-10-08 The Children's Medical Center Corporation Hsp90 inhibitors for the treatment of obesity and methods of use thereof
WO2016065042A1 (en) 2014-10-22 2016-04-28 Extend Biosciences, Inc. Therapeutic vitamin d conjugates
US9789197B2 (en) 2014-10-22 2017-10-17 Extend Biosciences, Inc. RNAi vitamin D conjugates
WO2016065052A1 (en) 2014-10-22 2016-04-28 Extend Biosciences, Inc. Insulin vitamin d conjugates
EP3481413A4 (en) * 2016-07-08 2020-01-08 Askgene Pharma, Inc. FUSION PROTEIN WITH LEPTIN AND METHOD FOR THE PRODUCTION AND USE THEREOF
HRP20231076T1 (hr) 2016-09-12 2023-12-22 Amryt Pharmaceuticals Inc. Postupci detektiranja neutralizirajućih protutijela protiv leptina
AU2023353057A1 (en) 2022-09-30 2025-05-01 Extend Biosciences, Inc. Long-acting parathyroid hormone

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5326700A (en) * 1990-11-06 1994-07-05 Eli Lilly And Company DNA sequences encoding t-PA derivatives with cleavable sites
ZA946122B (en) * 1993-08-17 1995-03-20 Amgen Inc Erythropoietin analogs
US6309853B1 (en) * 1994-08-17 2001-10-30 The Rockfeller University Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof
WO1996023815A1 (en) * 1995-01-31 1996-08-08 Eli Lilly And Company Ob gene product antibodies
DE69638119D1 (de) * 1995-11-22 2010-03-11 Amgen Inc Verfahren zur Erhöhung der mageren Fleischmasse mit Fettleibigkeitsprotein (OB) Zusammensetzungen
AU1406497A (en) * 1995-12-06 1997-06-27 Schering Corporation Mutational variants of mammalian ob gene proteins
JPH09176198A (ja) * 1995-12-28 1997-07-08 Kikkoman Corp 抗肥満タンパク質モノクローナル抗体及びハイブリドーマ
JP2000505791A (ja) * 1996-01-25 2000-05-16 イーライ・リリー・アンド・カンパニー 肥満症タンパク質類似体化合物およびその製剤
EP0827750A3 (en) * 1996-08-23 2002-11-20 Eli Lilly And Company Obesity protein formulations
WO1999023115A1 (en) * 1997-10-31 1999-05-14 Eli Lilly And Company Glycosylated obesity protein analogs
DE69921486T2 (de) * 1998-08-10 2006-02-02 Amgen Inc., Thousand Oaks Dextran-leptin konjugate, pharmazeutische zusammentsetzungen und verbundene verfahren
US6420339B1 (en) * 1998-10-14 2002-07-16 Amgen Inc. Site-directed dual pegylation of proteins for improved bioactivity and biocompatibility

Also Published As

Publication number Publication date
EP1151102B1 (en) 2006-04-19
CY1107470T1 (el) 2012-12-19
AU3362300A (en) 2000-08-29
WO2000047741A1 (en) 2000-08-17
ES2257287T3 (es) 2006-08-01
JP4841037B2 (ja) 2011-12-21
DE60027409D1 (de) 2006-05-24
PT1151102E (pt) 2006-07-31
ATE323766T1 (de) 2006-05-15
CA2359840C (en) 2012-10-23
DE60027409T2 (de) 2007-04-12
EP1151102A1 (en) 2001-11-07
CA2359840A1 (en) 2000-08-17
JP2002536018A (ja) 2002-10-29
AU781460B2 (en) 2005-05-26

Similar Documents

Publication Publication Date Title
DK1151102T3 (da) Glycosylerede leptinpræparater og relaterede fremgangsmåder
AU2001254624A1 (en) Human coagulation factor vii variants
EP1484339A3 (en) Kallikrein-inhibiting "Kunitz Domain" proteins and nucleic acids encoding the same
BRPI0410164A (pt) composições e métodos para preparação de mutantes de glicosilação de hormÈnio do crescimento humano
WO2000034317A3 (en) Method for reducing immunogenicity of proteins
EP2325205A3 (en) Crystals of whole antibodies and fragments thereof and methods for making and using them
WO2003059934A3 (en) Albumin fusion proteins
BR0007840A (pt) Proteìnas de fusão her-2/neu
DK1005540T3 (da) IKK-beta-proteiner, nukleinsyrer og fremgangsmåder
YU48703A (sh) Novi interferonu beta-slični molekuli
DK1904635T3 (da) Glycosyleret IL-7, fremstilling og anvendelser
DK0471011T4 (da) Humant lactoferrin-cDNA-sekvens
EP0797999A3 (en) Formulations of obesity protein
DK0750672T3 (da) DNA-sekvenser for matrix-metalproteaser, deres tilvejebringelse og anvendelse
IL81221A0 (en) Dna sequences coding for proteins having the biological activity of husi-type i inhibitors,biotechnological methods for preparing said proteins and pharmaceutical compositions containing them
DK0877803T3 (da) OB-proteinreceptor og relaterede sammensætninger og fremgangsmåder
HUP0100267A2 (hu) Helicobacter pylori eredetű nukleinsav- és aminosav-szekvenciák és a megfelelő nukleinsavakat vagy peptideket tartalmazó vakcina-készítmények
EP1801123A3 (en) Crystals of whole antibodies and fragments thereof and methods for making and using them
WO2003008449A8 (en) Ntb-a, a surface molecule involved in natural killer cells activity
FI964186A0 (fi) Ei-liittävät gp350/220-variantit
DK1219301T3 (da) Vacciner, som indeholder hybridpolypeptider, der består af mindst to forskellige allergene proteiner
CA2002833A1 (en) Interferon-gamma binding proteins
ATE331032T1 (de) Glutamine: fructose-6-phosphat amidotransferase (gfat), ihre herstellung und verwendung
AUPM772494A0 (en) Improvements in production of proteins in host cells
BR0211991A (pt) HormÈnio do crescimento humano modificado